Larisa Reyderman

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 4.7K citations · Full text

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 757 citations · Full text

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 366 citations · Full text

Dna Damage, Molecular Biology, Pathology +18

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Eric McDade, Jeffrey L. Cummings, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2022 · 260 citations · Full text

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Lawrence S. Honig, Jerome Barakos, Shobha Dhadda et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2023 · 101 citations · Full text